Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3286 to 3300 of 7685 results

  1. Indicator advisory committee (IAC)

    We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...

  2. Managed access

    Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  3. Artificial intelligence (AI) and digital regulations service

    NICE's leading role in designing a new service to support the development and adoption of AI and data-driven technologies in health and care.

  4. Life sciences: how to get your product to market

    Support for industry to engage with NICE during all stages of health technology development

  5. Commercial Liaison Team

    The Commercial Liaison Team (CLT) works with companies who are considering a patient access scheme for their drug or treatment. Patient access schemes

  6. What we do

    Role and responsibilities of the National Institute of Health and Care Excellence

  7. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals

  8. Past appeals and decisions

    Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic

  9. Kidney conditions: CKD - ACEi and ARB (IND263)

    This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247

    General practice indicators suitable for use outside of QOF
    Published
    21 August 2023

  10. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer . Patient decision aid on intrabeam radiotherapy for treating early breast cancer

    Decision aid for Intrabeam radiotherapy system for adjuvant treatment of early breast cancer, TA501 c NICE 2018. All rights reserved. Subject to...

  11. Study NICE and LSE's Executive MSc Healthcare Decision-Making

    Study NICE and LSE's Executive MSc Healthcare Decision-Making

  12. NICE Advice service

    NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.

  13. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation

  14. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  15. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel